Bloom Burton Has Optimistic Outlook of TSE:MDP Q3 Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Equities research analysts at Bloom Burton boosted their Q3 2025 earnings per share (EPS) estimates for Medexus Pharmaceuticals in a research note issued on Thursday, January 23rd. Bloom Burton analyst D. Martin now expects that the company will earn $0.10 per share for the quarter, up from their previous estimate of $0.04. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Bloom Burton also issued estimates for Medexus Pharmaceuticals’ FY2025 earnings at $0.17 EPS, FY2026 earnings at ($0.24) EPS and FY2027 earnings at $0.69 EPS.

Several other research firms have also issued reports on MDP. Raymond James raised shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price target on the stock in a research report on Wednesday, January 8th. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Stifel Nicolaus lifted their price target on Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research report on Tuesday, January 14th. Ventum Cap Mkts raised Medexus Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 17th. Finally, Leede Financial raised Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, January 22nd. One analyst has rated the stock with a buy rating and five have given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Strong Buy” and a consensus price target of C$5.58.

Medexus Pharmaceuticals Stock Performance

MDP stock opened at C$3.99 on Monday. Medexus Pharmaceuticals has a fifty-two week low of C$1.47 and a fifty-two week high of C$5.56. The stock has a fifty day moving average of C$3.33 and a 200-day moving average of C$2.75. The company has a market capitalization of C$97.87 million, a price-to-earnings ratio of 79.80 and a beta of 1.96.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.